All Clarivate websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
Philadelphia’s Mineralys Therapeutics Inc. has secured a further $118 million to develop MLS-101, a potential hypertension drug in-licensed from Mitsubishi Tanabe Pharma Corp.
